Trade Names:Fragmin- Injection 2,500 units (16 mg per 0.2 mL)- Injection 5,000 units (32 mg per 0.2 mL)- Injection 7,500 units (48 mg per 0.3 mL)- Injection 10,000 units (64 mg per mL)- Injection 12,500 units (80 mg per 0.5 mL)- Injection 15,000 units (96 mg per 0.6 mL)- Injection 18,000 units (115.2 mg per 0.72 mL) in prefilled syringes- Injection 95,000 units per 3.8 mL (160 mg per mL)- Injection 95,000 units per 9.5 mL (64 mg per mL) in multiple-dose vials
Inhibits reactions that lead to clotting.
Bioavailability is approximately 87%.
T max is approximately 4 h.
Vd is 40 to 60 mL/kg.
The t ½ is 3 to 5 h.
Prophylaxis of ischemic complications in unstable angina and non–Q-wave MI in patients on aspirin therapy; prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients undergoing hip replacement surgery, in patients undergoing abdominal surgery who are at risk for thromboembolic complications, or in patients who are at risk of thromboembolic complications due to severely restricted mobility during acute illness; extended treatment of symptomatic venous thromboembolism (VTE) (proximal DVT and/or PE) to reduce recurrence of VTE in patients with cancer.
Active major bleeding; thrombocytopenia associated with positive in vitro tests for antiplatelet antibody; patients undergoing regional anesthesia for unstable angina or non–Q-wave MI; hypersensitivity to heparin or pork products or to any component of the product. Patients with cancer undergoing anesthesia should not receive dalteparin for extended treatment of symptomatic VTE.
Subcutaneous 120 units/kg of body weight (max, 10,000 units) every 12 h with aspirin (75 to 165 mg/day, unless contraindicated) therapy. Continue treatment until patient is clinically stabilized, usually 5 to 8 days.DVT Prophylaxis (Hip Replacement Surgery)Adults
Subcutaneous If started postoperatively, 2,500 units within 4 to 8 h after surgery, followed by 5,000 units/day for 5 to 10 days; if started preoperatively on day of surgery, 2,500 units within 2 h before surgery, followed by 2,500 units 4 to 8 h after surgery and continued at 5,000 units/day for 5 to 10 days; if started preoperatively on the evening before surgery, 5,000 units 10 to 14 h before surgery, followed by 5,000 units 4 to 8 h after surgery and continued at 5,000 units/day for 5 to 10 days.DVT Prophylaxis (Abdominal Surgery)Adults
Subcutaneous 2,500 units starting 1 to 2 h before surgery and continuing every day for 5 to 10 days.Medical Patients With Severely Restricted Mobility During Acute IllnessAdults
Subcutaneous 5,000 units/day for 12 to 14 days.Extended Treatment of Symptomatic Venous Thromboembolism in Cancer PatientsAdults
Subcutaneous For the first 30 days of treatment, give 200 units/kg once daily (max, 18,000 units/day). Months 2 to 6: Administer 150 units/kg once daily (max, 18,000 units/day).
In patients with platelet counts between 50,000 and 100,000/mm 3 , reduce dose to 2,500 units once daily until platelet count recovers to at least 100,000 units/mm 3 . In patients who experience platelet counts below 50,000 units/mm 3 , discontinue dalteparin until platelet count recovers to 50,000 units/mm 3 .
In patients with severe renal function impairment (CrCl less than 30 mL/min), monitor for anti-Xa levels to determine dalteparin dose. Target anti-Xa range is 0.5 to 1.5 units/mL. Sampling should be performed 4 to 6 h after dosing and only after 3 to 4 doses have been given.
Store at 68° to 77°F.
Increased risk of bleeding.
Dalteparin caused increased concentrations.
Alopecia, skin necrosis (postmarketing).
Any bleeding event (19%); major bleeding events (6%).
Injection-site hematoma (5%); wound hematoma (3%); injection-site pain (at least 2%).
Allergic reactions, including pruritus, rash, fever, injection-site reaction, or bullous eruption; anaphylactoid reactions.
Risk of spinal/epidural hematoma, which can result in long-term or permanent paralysis, is increased in patients receiving neuraxial anesthesia or spinal puncture who are anticoagulated with LMWHs or heparinoids. Other risk factors include indwelling epidural catheters, repeated/traumatic epidural/spinal puncture, or use of other drugs affecting hemostasis (eg, NSAIDs, platelet inhibitors, anticoagulants). Frequently monitor for signs or symptoms of neurological impairment.
Periodic routine CBC, including platelet count, blood chemistry, and stool occult blood tests, is recommended; anticoagulant effect can be monitored by using anti-factor Xa in patients with severe renal function impairment or if abnormal coagulation parameters or bleeding occur.
Category B .
Safety and efficacy not established.
Use very cautiously in patients with history of heparin-induced thrombocytopenia.
Cannot be exchanged on a unit-per-unit basis with other types of heparin.
Avoid use in patients at risk for bleeding (eg, severe hypertension, severe liver or kidney disease, platelet defects, recent GI bleeding) or shortly after brain, spinal, or ophthalmological surgery.
The multiple-dose vial of dalteparin contains benzyl alcohol as a preservative, which has been associated with fatal “gasping syndrome” in premature infants.
Copyright © 2009 Wolters Kluwer Health.